NEWS

WIRES

OTHER

Multiple Sclerosis: MedDEV's Susan B.B. Lim Schabacker Says New Research Points to Histamine as an Important Link in MS Treatment

NEW RESEARCH POINTS TO HISTAMINE AS AN IMPORTANT LINK IN MS TREATMENT

Elaine DeLack, CEO of EDMS LLC (http://www.edmsllc.com), is pleased to note that histamine, a long-overlooked treatment for multiple sclerosis (MS), is in the news again. She cites comments made by Deputy Editor of the Journal of Leukocyte Biology, John Wherry, Ph.D., describing recent animal research as "very exciting for several reasons."

DeLack references a successful track record in treating MS patients with Prokarin, a transdermal histamine treatment, as largely unpublicized. Prokarin, developed by DeLack, has provided an effective way of lessening and alleviating MS symptoms since 1999. Over 7,000 patients have used Prokarin, and 90 percent of those who are heat sensitive have reported improvement in their symptoms to varying degrees. Some have referred to DeLack, CEO of EDMS LLC, as a "quack," even though Prokarin has become an effective treatment option for thousands of individuals suffering from MS.

On January 31, 2011, Science Daily reported new research that may confirm what DeLack has long known - that histamine may be an important molecule in developing new treatments for MS. Scientists at the Neuroimmunology and Neuromuscular Disorders Unit at the Neurological Institute Foundation Carlo Besta in Milan, Italy, have found that administering histamine to mice, in the mouse model of MS, reduced the proliferation of myelin autoreactive T lymphocytes and the production of interferon-gamma, which is a cytokine involved with brain inflammation and demyelination.

Wherry said that the new research "points to [an] unexpected connection between these pathways involved in autoimmunity and allergy, and suggests previously unrecognized connections between these very different types of immune responses." He further noted that "while extending studies in animal models such as these to humans takes substantially more work, these new data point to a potentially novel drug target for MS and possible other autoimmune or central nervous system diseases." Since the inception of Prokarin in 1999, additional research investigating the potential of histamine as a treatment for MS has been conducted, and doctors at the Department of Molecular and Integrative Physiology at the University of Kansas Medical Center reported histamine(H2) receptor activation significantly reduced clinical signs of MS in the animal (EAE) model of MS. Although nearly forgotten, successful treatment with IV histamine infusions brought thousands of MS patients in the 1950s from all over the world to Dr. Hinton Jonez at St. Joseph's Hospital in Tacoma, WA. In fact, McCall's Magazine, in December 1950, reported that Dr. Jonez' work with histamine infusions was "miraculous" in treating MS symptoms.

The struggle for Prokarin's acceptance in mainstream medicine has been well documented in the book, "They Said it Didn't Make Cents: MS - The Prokarin Story," after DeLack experienced resistance and apathy from the National Multiple Sclerosis Society and pharmaceutical companies.

While Science Daily's recent article suggests that histamine offers "unexpected" potential for MS treatment, the transdermal histamine treatment, Prokarin, has already helped many MS patients and holds a promising future for individuals with other autoimmune or central nervous system diseases.

Contact: Susan B.B. Lim Schabacker

336-577-9454

susanschabacker@gmail.com

HTML: http://www.eworldwire.com/pressreleases/212446

PDF: http://www.eworldwire.com/pdf/212446.pdf

ONLINE NEWSROOM: http://www.eworldwire.com/newsroom/317738

MedDEV Inc
17317 East Lake Goodwin Road
Stanwood, WA 98292
PHONE. 360-654-0288
EMAIL: elaine.delack@meddevinc.com

Susan Schabacker
MedDEV Inc
PHONE. 336-577-9454